ATE237332T1 - Efavirenz enthaltende gepresste tablettenformulierug - Google Patents

Efavirenz enthaltende gepresste tablettenformulierug

Info

Publication number
ATE237332T1
ATE237332T1 AT99925793T AT99925793T ATE237332T1 AT E237332 T1 ATE237332 T1 AT E237332T1 AT 99925793 T AT99925793 T AT 99925793T AT 99925793 T AT99925793 T AT 99925793T AT E237332 T1 ATE237332 T1 AT E237332T1
Authority
AT
Austria
Prior art keywords
tablet formulation
formulation containing
efavirenz
pressed tablet
containing efavirenz
Prior art date
Application number
AT99925793T
Other languages
English (en)
Inventor
Udit Batra
Raymond J Higgins
Karen C Thompson
Ashok V Katdare
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815800.9A external-priority patent/GB9815800D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE237332T1 publication Critical patent/ATE237332T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99925793T 1998-05-27 1999-05-24 Efavirenz enthaltende gepresste tablettenformulierug ATE237332T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8692198P 1998-05-27 1998-05-27
GBGB9815800.9A GB9815800D0 (en) 1998-07-21 1998-07-21 Compressed tablet formulation
PCT/US1999/011464 WO1999061026A1 (en) 1998-05-27 1999-05-24 Efavirenz compressed tablet formulation

Publications (1)

Publication Number Publication Date
ATE237332T1 true ATE237332T1 (de) 2003-05-15

Family

ID=26314071

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99925793T ATE237332T1 (de) 1998-05-27 1999-05-24 Efavirenz enthaltende gepresste tablettenformulierug

Country Status (14)

Country Link
EP (1) EP1083901B1 (de)
JP (1) JP4000354B2 (de)
AT (1) ATE237332T1 (de)
AU (1) AU761182B2 (de)
CA (1) CA2332876C (de)
CO (1) CO5070643A1 (de)
CY (1) CY1113191T1 (de)
DE (1) DE69906963D1 (de)
DK (1) DK1332757T3 (de)
ES (1) ES2388849T3 (de)
PE (1) PE20000559A1 (de)
PT (1) PT1332757E (de)
SI (1) SI1332757T1 (de)
WO (1) WO1999061026A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
JP2006504409A (ja) 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
US7198653B2 (en) * 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
JP2005089396A (ja) * 2003-09-19 2005-04-07 Pola Chem Ind Inc イソフラボン含有経口投与組成物
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
US20090088424A1 (en) * 2007-08-17 2009-04-02 Ilan Zalit Methods and compositions for controlling the bioavailability of poorly soluble drugs
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
HUE029853T2 (en) 2010-05-11 2017-04-28 Janssen Pharmaceutica Nv Pharmaceutical formulations containing 1- (beta-D-Glucopyranosyl) -2-thienylmethylbenzene derivatives as SGLT inhibitors
EP2441759A1 (de) 2010-10-14 2012-04-18 Lonza Ltd. Verfahren zur Synthese von zyklischen Carbamaten
EP2447255A1 (de) 2010-10-14 2012-05-02 Lonza Ltd. Verfahren zur Synthese von zyklischen Carbamaten
RU2661402C2 (ru) * 2011-10-17 2018-07-16 Лексикон Фармасьютикалз, Инк. Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции
CN113499441A (zh) * 2021-08-05 2021-10-15 上海合全医药有限公司 一种药用糖包衣液及其制备方法
CN113999543B (zh) * 2021-10-29 2022-11-04 广西华纳新材料股份有限公司 一种钙-硅核壳结构纳米碳酸钙的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente

Also Published As

Publication number Publication date
CY1113191T1 (el) 2016-04-13
PT1332757E (pt) 2012-09-03
DE69906963D1 (de) 2003-05-22
EP1083901B1 (de) 2003-04-16
JP4000354B2 (ja) 2007-10-31
WO1999061026A1 (en) 1999-12-02
PE20000559A1 (es) 2000-07-05
AU4201099A (en) 1999-12-13
SI1332757T1 (sl) 2012-10-30
JP2002516281A (ja) 2002-06-04
CO5070643A1 (es) 2001-08-28
ES2388849T3 (es) 2012-10-19
CA2332876C (en) 2008-07-08
CA2332876A1 (en) 1999-12-02
EP1083901A1 (de) 2001-03-21
AU761182B2 (en) 2003-05-29
DK1332757T3 (da) 2012-09-24

Similar Documents

Publication Publication Date Title
ATE237332T1 (de) Efavirenz enthaltende gepresste tablettenformulierug
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
EP1268412B8 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
SE9500422D0 (sv) New oral pharmaceutical dosage forms
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
HK1049103A1 (zh) 含有利托那韋(abt-538)並與茚地那韋(mk-639)結合藥物的組合物以及他們在治療艾滋病中的用途
ES2145913T3 (es) Inhibidores de metaloproteasas.
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
HUP0401998A2 (hu) PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
MY136173A (en) 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
TR200101261T2 (tr) Uzun süreli salınımlı ranolazin formülasyonları.
BG103425A (en) Pharmaceutical composition
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
ATE291914T1 (de) Zolmitriptanhaltige arzneizusammensetzungen
HUP0004544A2 (hu) Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
MXPA02012160A (es) Composiciones medicinales las cuales contienen derivados de propenona.
HUP0400553A2 (hu) Gyógyászati készítmények
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
CA2417935A1 (en) Anti-inflammatory medicament
SE0001916D0 (sv) Novel formulation
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
HK1029277A1 (en) Pharmaceutical coating composition and method of use.

Legal Events

Date Code Title Description
REZ Deleted due to withdrawal
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties